(Press-News.org) Contact information: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Elsevier's Maturitas publishes position statement on fertility preservation
Amsterdam, November 6, 2013 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on the topic of fertility preservation.
The rising need for fertility preservation results from two new 21st century changes. Improved survival of malignant disease with gonadotoxic treatments means that long-term reproductive potential should now be considered. Delaying childbirth means that the use of fertility preservation techniques to counter the normal age-related decline in fertility is also becoming a topic of interest for many healthy women.
This EMAS position paper provides and critically appraises evidence on available options for fertility preservation in both pre-pubertal and post-pubertal men and women. EMAS position paper recommends that all men and women of reproductive age should be thoroughly informed before the initiation of any gonadotoxic treatment about the possible risks of the treatment in question and all available options of fertility preservation should be discussed. Fertility preservation should be a priority when treating children or adults of reproductive age with agents that may have hazardous effects on the reproductive system and gonadotoxicity should be kept at a minimum.
These and other recommendations presented in the EMAS' position statement on fertility preservation are published in the article: "EMAS Position statement: Fertility preservation," published in Maturitas, Elsevier; available online on ScienceDirect.
###
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact newsroom@elsevier.com Journalists wishing to interview the authors may contact Greyling Peoples, +31 20 485 3323; g.peoples@elsevier.com or editor of Maturitas, Margaret Rees margaret.rees@hotmail.co.uk.
"EMAS Position statement: Fertility preservation" by Gesthimani Mintziori, Irene Lambrinoudaki, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Faustino R. Pérez-López, Karin Schenck-Gustafsson, Yvonne van der Schouw, Tommaso Simoncini, Florence Tremollieres, Basil C. Tarlatzis, Margaret Rees and Dimitrios G. Goulis. Published in Maturitas (Elsevier), In Press; DOI: 10.1016/j.maturitas.2013.10.010.
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date.http://www.emas-online.org
About Maturitas
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Greyling Peoples
Elsevier
+31 20 485 3323
g.peoples@elsevier.com
Elsevier's Maturitas publishes position statement on fertility preservation
2013-11-06
ELSE PRESS RELEASES FROM THIS DATE:
Personal reflection triggers increased brain activity during depressive episodes
2013-11-06
Personal reflection triggers increased brain activity during depressive episodes
Research by the University of Liverpool has found that people experiencing depressive episodes display increased brain activity when they think about themselves.
Using functional ...
Maintaining strength in ocean science requires greater collaboration, coordination, and integration
2013-11-06
Maintaining strength in ocean science requires greater collaboration, coordination, and integration
Expert Panel Report on Canadian Ocean Science
Ottawa (November 6, 2013) – A new expert panel report, by the Council of Canadian Academies, ...
Genetic aberration paves the way for new treatment of cancer disease
2013-11-06
Genetic aberration paves the way for new treatment of cancer disease
12-15 years of development and millions of dollars are typically the costs, when companies develop a new anti-cancer drug. Therefore all short cuts to a treatment are welcome. Researchers at ...
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer
2013-11-06
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer
Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference ...
For young baseball players, light bats don't hit too fast
2013-11-06
For young baseball players, light bats don't hit too fast
PROVIDENCE, R.I. [Brown University] — With some fierce pitching on display, this year's World Series featured its share of shattered wood bats. That's a problem many youth baseball players avoid by using ...
'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's
2013-11-06
'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's
New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs ...
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study
2013-11-06
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study
Results of an EORTC study published in Cancer point out the prognostic value of baseline recorded health-related quality of life for survival for ...
Nature's great diversity: Remarkable 277 new wasp species from Costa Rica
2013-11-06
Nature's great diversity: Remarkable 277 new wasp species from Costa Rica
Costa Rica reveals astonishing biodiversity of braconid wasps, with 277 new species of the tribe Heterospilini described in the latest special issue of the open access journal ZooKeys.
This is the second ...
Touch may alleviate existential fears for people with low self-esteem
2013-11-06
Touch may alleviate existential fears for people with low self-esteem
As human beings, we all know that we are going to die some day. Most of us deal with this knowledge by trying to live meaningful lives, but people with low self-esteem ...
NIST's new compact atomic clock design uses cold atoms to boost precision
2013-11-06
NIST's new compact atomic clock design uses cold atoms to boost precision
Physicists at the National Institute of Standards and Technology (NIST) have demonstrated a compact atomic clock design that relies on cold rubidium atoms instead ...